Porth Ymchwil

All Wales Medicines Strategy Group Final Appraisal Report - Icatibant (Firazyr) for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults (with C1-esterase-inhibitor deficiency).

Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

StandardStandard

All Wales Medicines Strategy Group Final Appraisal Report - Icatibant (Firazyr) for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults (with C1-esterase-inhibitor deficiency). / Hughes, D.; Hughes, D.A.; All Wales Strategy Group., [No Value].
2008 gol. Unknown, 2008.

Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

HarvardHarvard

Hughes, D, Hughes, DA & All Wales Strategy Group., NV 2008, All Wales Medicines Strategy Group Final Appraisal Report - Icatibant (Firazyr) for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults (with C1-esterase-inhibitor deficiency). 2008 gol., Unknown.

APA

Hughes, D., Hughes, D. A., & All Wales Strategy Group., N. V. (2008). All Wales Medicines Strategy Group Final Appraisal Report - Icatibant (Firazyr) for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults (with C1-esterase-inhibitor deficiency). (2008 gol.) Unknown.

CBE

Hughes D, Hughes DA, All Wales Strategy Group. NV 2008. All Wales Medicines Strategy Group Final Appraisal Report - Icatibant (Firazyr) for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults (with C1-esterase-inhibitor deficiency). 2008 gol. Unknown.

MLA

Hughes, D., D.A. Hughes a [No Value] All Wales Strategy Group. All Wales Medicines Strategy Group Final Appraisal Report - Icatibant (Firazyr) for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults (with C1-esterase-inhibitor deficiency). 2008 udg. Unknown. 2008.

VancouverVancouver

Hughes D, Hughes DA, All Wales Strategy Group. NV. All Wales Medicines Strategy Group Final Appraisal Report - Icatibant (Firazyr) for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults (with C1-esterase-inhibitor deficiency). 2008 gol. Unknown, 2008.

Author

Hughes, D. ; Hughes, D.A. ; All Wales Strategy Group., [No Value]. / All Wales Medicines Strategy Group Final Appraisal Report - Icatibant (Firazyr) for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults (with C1-esterase-inhibitor deficiency). 2008 gol. Unknown, 2008.

RIS

TY - BOOK

T1 - All Wales Medicines Strategy Group Final Appraisal Report - Icatibant (Firazyr) for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults (with C1-esterase-inhibitor deficiency).

AU - Hughes, D.

AU - Hughes, D.A.

AU - All Wales Strategy Group., [No Value]

PY - 2008/1/1

Y1 - 2008/1/1

UR - http://www.wales.nhs.uk/sites3/Documents/371/icatibant%20_Firazyr_%20FAR%20revised_Jerini%20CIC%20check.pdf

M3 - Commissioned report

BT - All Wales Medicines Strategy Group Final Appraisal Report - Icatibant (Firazyr) for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults (with C1-esterase-inhibitor deficiency).

PB - Unknown

ER -